CoChat

T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing

Published version of a preprint

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

T cell–retargeting therapies have transformed the therapeutic landscape for hematologic diseases. T cell–dependent bispecific antibodies (TDB) function as conditional agonists that induce a polyclonal T-cell response, resulting in target cell destruction and cytokine release. The relationship between this response and its effects on surrounding innate immune populations has not been fully explored. Here we show that treatment with mosunetuzumab in patients results in natural killer (NK) cell activation in the peripheral blood. We modeled this phenomenon in vitro and found that TDB-mediated killing activated NK cells, increasing NK function and antibody-dependent cellular cytotoxicity (ADCC), and enhanced the capability of macrophages to perform antibody-dependent cellular phagocytosis (ADCP). This enhancement was triggered by cytokines released through TDB treatment, with IL2 and IFNγ being major drivers for increased ADCC and ADCP, respectively. Surprisingly, cytolytic ability could be further augmented through neutralization of IL10 for NK cells and TNFα for macrophages. Finally, we showed that TDB treatment enhanced the efficacy of Fc-driven killing to an orthogonal solid tumor target in vivo. These results provide rationale for novel antibody therapy combinations that take advantage of both adaptive and innate immune responses.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-23-0072

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. Zahavi, 2018, Enhancing antibody-dependent cell-mediated cytotoxicity (ADCC): a strategy for improving antibody-based immunotherapy, Antib Ther, 1, 7
  2. Tripp, 1993, Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist, 3725

Cited by

See all 16

Metadata

Authors
Besla, R., Penuel, E., Del Rosario, G., Cosino, E., Myrta, S., Dillon, M., Lazar, G. A., Nickles, D., Spiess, C., Yu, S.-F., & Polson, A. G.
Affiliations
  • Genentech (US)
  • 1Genentech Research and Early Development, Genentech Inc., South San Francisco, California.
  • F. Hoffmann-La Roche AG (CH)
Venue
Cancer Immunology Research
Published
2023-10-27
Volume
12
Issue
1
Pages
60-71
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W4388014101
Cited by
13
References
34
Citations by year
2026: 4 · 2025: 6 · 2024: 3
FWCI
1.42
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Genentech
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
mosunetuzumab, NK cell activation, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, macrophages, innate immune activation, interleukin-2, interferon-gamma, IL-10, TNF-α, cytokine production, solid tumors, hematologic disorders, antibody combination therapy
MeSH terms
Antibody-Dependent Cell Cytotoxicity, Humans, Immunity, Innate, T-Lymphocytes, Cytokines, Antibodies, Bispecific, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing. https://app.cochat.ai/papers/10.1158/2326-6066.cir-23-0072
The paper
Besla, R., Penuel, E., Del Rosario, G., Cosino, E., Myrta, S., Dillon, M., Lazar, G. A., Nickles, D., Spiess, C., Yu, S.-F., & Polson, A. G. (2024). T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-23-0072

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.